Short Interest in Atrinsic Inc. (NASDAQ:PTIX) Decreases By 48.6%

Atrinsic Inc. (NASDAQ:PTIX) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totaling 46,200 shares, a decrease of 48.6% from the August 31st total of 89,900 shares. Approximately 2.7% of the shares of the company are sold short. Based on an average daily volume of 2,670,000 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 2,670,000 shares, the short-interest ratio is currently 0.0 days. Approximately 2.7% of the shares of the company are sold short.

Atrinsic Stock Down 0.3%

Shares of Atrinsic stock opened at $3.29 on Friday. The firm has a market cap of $1.94 million, a price-to-earnings ratio of -0.35 and a beta of 0.38. The business has a 50-day moving average price of $3.37 and a 200-day moving average price of $3.61. Atrinsic has a twelve month low of $2.25 and a twelve month high of $15.26.

Atrinsic (NASDAQ:PTIX) last issued its quarterly earnings data on Wednesday, September 10th. The company reported ($1.37) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Atrinsic from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th.

Atrinsic Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.